Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Clinical, real-world data reaffirming the long-term effectiveness of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and Gardasil (Human Papillomavirus 4-valent Vaccine, Recombinant) against certain HPV-related cancers and diseases will be presented at the EUROGIN International Multidisciplinary HPV Congress 2026 in Vienna, Austria, March 18-21.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Drugs & Targets

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) reduced the risk of event-free survival events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

Cancer Policy

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA has granted sacituzumab tirumotecan (sac-TMT), a trophoblast cell-surface antigen 2 directed antibody-drug conjugate, a priority voucher via the agency’s Commissioner’s National Priority Voucher (CNPV) Pilot Program.

January 09, 2026

Vol.52 No.1

By Claire Marie Porter

Drugs & Targets

FDA approves Rybrevant Faspro for EGFR-mutated NSCLC

FDA approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneously administered therapy for patients with epidermal growth factor receptor-mutated non-small cell lung cancer.

January 09, 2026

Vol.52 No.1

Merck, Moderna initiate phase III INTerpath-002 study evaluating V940 (mRNA-4157) + Keytruda in NSCLC indication

YOU MAY BE INTERESTED IN

Merck to present long-term data of Gardasil 9 and Gardasil at the EUROGIN international multidisciplinary HPV Congress

Combination treatment may dramatically improve survival in brain cancer

Keytruda + Padcev reduced risk of EFS and death for muscle-invasive bladder cancer when given before and after surgery

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

Merck & Co. drug for treating NSCLC awarded FDA priority voucher

FDA approves Rybrevant Faspro for EGFR-mutated NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login